Project Narrative: This project seeks to develop a gallium-68 (68Ga) labeled radiopharmaceutical diagnostic imaging agent, 68Ga-tilmanocept, for positron emission tomography (PET) imaging of atherosclerotic plaques in the walls of arteries and characterization of their inflammatory microenvironments. This project will enable improved risk assessment and monitoring of therapies for individuals at risk for myocardial infarctions (heart attacks) and ischemic strokes, the leading causes of death worldwide. If successful, this project will significantly reduce the catastrophic burdens inflicted upon our society by these conditions.